Pfizer 10-Kyear ended 2025-12-31

Executive Summary

Pfizer’s FY2025 revenue fell 1.6% as declining Paxlovid and Comirnaty sales outweighed growth in its non-COVID portfolio; excluding those two products, revenue grew 6% operationally. Cost reductions supported margins, but impairments and spending on acquired research held back GAAP earnings, while dividends exceeded free cash flow. Pfizer is investing in oncology and obesity treatments to replace sales threatened by patent expirations, with an expected $1.5B exclusivity-related revenue impact in 2026. The investment case turns on whether new products and pipeline milestones can offset that erosion and mounting pricing pressure without further large write-downs.

Key Financial Highlights

• Revenue mix: Paxlovid fell $3.35B and Comirnaty fell $1.05B; revenue excluding both rose to $54.5B from $51.3B. Eliquis, Vyndaqel and oncology products contributed to that offset, but 12 products still generated 65% of total revenue.
• Earnings quality: $4.94B of asset impairments and $1.61B of acquired in-process R&D expense weighed on GAAP results. Adjusted net income was $18.4B vs GAAP net income of $7.77B; noncash impairments help explain why OCF exceeded net income, while payment timing and a $1.35B licensing outflow affected cash flow.
• Capital return: Cash dividends were $9.77B, above FCF. Pfizer made no share repurchases, and shares outstanding rose from 5.67B to 5.69B.
• Pricing and funding: Product revenue deductions rose 7.3% to $36.4B, underscoring rebate pressure. Net interest expense was $2.07B, down from $2.55B, despite broadly flat total debt.

Business Developments

Pfizer is reallocating resources toward oncology, cardiometabolic disease and weight management. It acquired clinical-stage obesity company Metsera in November for $8.0B of fair-value consideration, including contingent rights; the provisional allocation included $8.0B of identifiable in-process R&D and $2.2B of goodwill. Its 3SBio licensing deal added another clinical-stage program but incurred a $1.35B acquired in-process R&D charge. These investments broaden potential growth drivers, but their value depends on development and commercialization rather than current sales.

Management reported $5.1B of its targeted $5.7B cost-base savings through 2026 and $600M of a targeted $1.5B in manufacturing savings by the end of 2027. It also reported $800M of its targeted $1.0B in annual Seagen synergies by the end of 2026. Pfizer says $500M of FY2025 R&D savings will be reinvested in 2026. A commercial reorganization effective 01/01/2026 and the wind-down of Pfizer Ignite further concentrate resources on its core portfolio.

Risk Assessment

• Exclusivity and concentration: Expected patent and exclusivity losses during 2026–2030 threaten established brands; Eliquis generated 13% of FY2025 revenue, making replacement growth consequential.
• Pricing and access: Medicare’s negotiated Eliquis price began 01/01/2026, with Ibrance and Xtandi following in 2027; rebates, insurer controls and international procurement can further limit realized sales.
• Development and acquisition execution: Metsera, Seagen and licensed programs must deliver approvals and commercial returns; changed forecasts already contributed to $3.9B of in-process R&D impairments in FY2025.
• COVID-product demand: Infection patterns, vaccine recommendations and coverage make Paxlovid and Comirnaty sales difficult to forecast after their steep FY2025 declines.
• Product safety and operations: Oxbryta remains withdrawn following a finding that its benefits no longer outweighed its risks; manufacturing quality or supplier disruptions could also interrupt sales and trigger regulatory costs.
• Legal, cyber and international exposure: Patent and product litigation, sensitive-data attacks, trade policy and currency movements could affect results; international markets supplied 41% of revenue.

Strategic Outlook and Investor Actionables

Pfizer enters 2026 with savings programs nearing their targets, but the expected exclusivity drag and new Medicare prices raise the bar for portfolio growth. Management’s opportunity is to turn oncology and obesity investment into durable revenue while preserving cash available for dividends and development.

• Portfolio replacement: Track revenue excluding Comirnaty and Paxlovid against the expected $1.5B 2026 exclusivity impact; sustained growth must absorb patent erosion.
• Pipeline returns: Track Metsera and oncology clinical and regulatory milestones, alongside further impairments, to test whether acquisition spending is creating value.
• Cash and pricing: Track FCF against dividends and Eliquis sales under its negotiated Medicare price; a persistent cash shortfall would constrain investment flexibility.